Benefit Dinner October 8 in NYC Explores the Future of Psychedelic Medicine

Brad Burge, MAPS Director of Communications and Marketing
Media Requests:
Press Resources:

NEW YORK — On October 8, 2016, the Multidisciplinary Association for Psychedelic Studies (MAPS) will host Future of Psychedelic Medicine, an intimate dinner to benefit psychedelic psychotherapy research in Soho, New York City.

MAPS Founder and Executive Director, Rick Doblin, Ph.D., leading MDMA researchers Michael Mithoefer, M.D., Alicia Danforth, Ph.D., and others will hold a conversation about the path to developing psychedelic psychotherapy into a legal treatment, and the vision of a post-prohibition world. The evening will include exquisite food, fine wine, and the gracious hospitality of hosts Giancarlo and Stephanie Canavesio. All proceeds from the Future of Psychedelic Medicine will benefit MAPS’ research and education programs.

MAPS is blazing a trail towards legal and cultural acceptance of psychedelics as legitimate scientific and therapeutic tools. MAPS’ upcoming Phase 3 clinical trials are crucial to making MDMA-assisted psychotherapy into a legal treatment for PTSD, opening the doors for new models of healing trauma and personal growth.

MAPS has completed six international Phase 2 clinical trials of MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD)—with promising results—and is now preparing for Phase 3, the final stage of research required for U.S. Food and Drug Administration (FDA) approval. MAPS has formally requested an End of Phase 2 meeting with the FDA in fall 2016 to come to agreement on the design of the Phase 3 studies.

Phase 3 trials will require over a dozen clinical sites, more than 50 co-therapists, at least 400 participants, and substantially more financial support. MAPS has more than $10 million in hand or pledged of the roughly $25 million needed to complete Phase 3 and establish MDMA-assisted psychotherapy as a legally available treatment for the millions of people suffering from PTSD.

MAPS is a 501(c)(3) non-profit organization developing scientific, medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS has disbursed over $26 million—all donated by individuals and family foundations—to psychedelic therapy and medical marijuana research, education, and harm reduction.

Special thanks to host committee members Maeve Rockefeller, Jim Apteker, Susan Brody, Sheila Burgel, Darren Fortunato, Stefanie Frank, Bailey Gimbel, Neal M. Goldsmith, Ph.D., Joshua Mailman, Rodrigo Niño, Daniel Pinchbeck, Patricia Steele, and Monica Winsor.

This event takes place during the Horizons: Perspectives on Psychedelics conference in New York City from October 7-9, 2016.

About the Event:

What: Future of Psychedelic Medicine: Dinner to Benefit Psychedelic Therapy Research

When: Saturday, October 8, 2016 / Doors at 7:00pm / Dinner at 8:00pm

Where: Soho, New York, NY

Tickets: $250 Single / $400 Pair


Phone: (831) 429-6362